<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="add48643-bcf3-4426-b9c1-06fa82b27b78"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for DOXYCYCLINE HYCLATE DELAYED-RELEASE TABLETS. <br/>
      <br/>DOXYCYCLINE HYCLATE delayed-release tablets, for oral use. <br/>Initial U.S. Approval: 1967</title>
   <effectiveTime value="20250414"/>
   <setId root="f9c63af9-d613-43fc-b8e5-ab6219f24c70"/>
   <versionNumber value="11"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="867220261" root="1.3.6.1.4.1.519.1"/>
            <name>Mayne Pharma Commercial LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="756003745" root="1.3.6.1.4.1.519.1"/>
                        <name>Mayne Pharma International Pty Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="118812386" root="1.3.6.1.4.1.519.1"/>
                        <name>Catalent Greenville, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="b91eed5a-aa60-4060-9bf0-9ff5359e7607"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250331"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51862-709" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxycycline Hyclate</name>
                        <formCode code="C42905" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, DELAYED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="50" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Doxycycline Hyclate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lactose Monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Lauryl Sulfate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Starch, Corn</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="87Y6436BKR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="120" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-709-12" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="completed"/>
                                 <effectiveTime>
                                    <low value="20160526"/>
                                    <high value="20240731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050795" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA AUTHORIZED GENERIC"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="completed"/>
                           <effectiveTime>
                              <low value="20160526"/>
                              <high value="20240731"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>containing yellow pellets</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="11" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;V</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="51862-571" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Doxycycline Hyclate</name>
                        <formCode code="C42905" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, DELAYED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Doxycycline Hyclate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="80" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="19XTS3T51U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Doxycycline Hyclate</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="334895S862" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Doxycycline Anhydrous</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Lauryl Sulfate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Talc</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Lactose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Starch, Corn</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (120 .MU.M)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Lactose Monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Microcrystalline Cellulose</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="87Y6436BKR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="51862-571-30" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20201002"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050795" root="2.16.840.1.113883.3.150"/>
                           <code code="C73605" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA AUTHORIZED GENERIC"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20201002"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>containing yellow pellets</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">D;8</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="e6bb2819-21d8-4775-aa3f-fe700f4b303c"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Severe Skin Reactions (<linkHtml href="#S5.5">5.5</linkHtml>)<br/>03/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="f4f68a2f-f859-413f-84ba-07a604e245af"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are a tetracycline-class drug indicated for:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Rickettsial infections (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>Sexually transmitted infections (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                           <item>Respiratory tract infections (<linkHtml href="#S1.3">1.3</linkHtml>)</item>
                           <item>Specific bacterial infections (<linkHtml href="#S1.4">1.4</linkHtml>)</item>
                           <item>Ophthalmic infections (<linkHtml href="#S1.5">1.5</linkHtml>)</item>
                           <item>Anthrax, including inhalational anthrax (post-exposure) (<linkHtml href="#S1.6">1.6</linkHtml>)</item>
                           <item>Alternative treatment for selected infections when penicillin is contraindicated (<linkHtml href="#S1.7">1.7</linkHtml>)</item>
                           <item>Adjunctive therapy in acute intestinal amebiasis and severe acne (<linkHtml href="#S1.8">1.8</linkHtml>)</item>
                           <item>Prophylaxis of malaria (<linkHtml href="#S1.9">1.9</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Usage</content>
                        </paragraph>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, Doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (<linkHtml href="#S1.10">1.10</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="6757fb12-66a7-4f8e-95c2-eb6957f222d5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Rickettsial Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by <content styleCode="italics">Rickettsiae</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="1b7d1507-6ad4-4305-9feb-8efb441c6181"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Sexually Transmitted Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of the following sexually transmitted infections:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Uncomplicated urethral, endocervical or rectal infections caused by <content styleCode="italics">Chlamydia trachomatis.</content>
                           </item>
                           <item>Nongonococcal urethritis caused by <content styleCode="italics">Ureaplasma urealyticum</content>.</item>
                           <item>Lymphogranuloma venereum caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                           <item>Granuloma inguinale caused by <content styleCode="italics">Klebsiella granulomatis</content>.</item>
                           <item>Uncomplicated gonorrhea caused by <content styleCode="italics">Neisseria gonorrhoeae.</content>
                           </item>
                           <item>Chancroid caused by <content styleCode="italics">Haemophilus ducreyi</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="86780de7-8575-4ab9-8bbf-34d0019e18c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3	Respiratory Tract Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of the following respiratory infections:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Respiratory tract infections caused by <content styleCode="italics">Mycoplasma pneumoniae</content>. Psittacosis (ornithosis) caused by <content styleCode="italics">Chlamydophila psittaci</content>.</item>
                           <item>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</item>
                           <item>Doxycycline is indicated for treatment of infections caused by the following micro- organisms, when bacteriological testing indicates appropriate susceptibility to the drug:<list listType="unordered">
                                 <item>
                                    <caption>–</caption> Respiratory tract infections caused by <content styleCode="italics">Haemophilus influenzae</content>.</item>
                                 <item>
                                    <caption>–</caption> Respiratory tract infections caused by <content styleCode="italics">Klebsiella</content> species.</item>
                                 <item>
                                    <caption>–</caption> Upper respiratory infections caused by <content styleCode="italics">Streptococcus pneumoniae</content>.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.4">
                     <id root="06cd3042-f91e-4a46-810f-03d92ae64bb4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4	Specific Bacterial Infections </title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of the following specific bacterial infections:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Relapsing fever due to <content styleCode="italics">Borrelia recurrentis</content>.</item>
                           <item>Plague due to <content styleCode="italics">Yersinia pestis</content>.</item>
                           <item>Tularemia due to <content styleCode="italics">Francisella tularensis</content>.</item>
                           <item>Cholera caused by <content styleCode="italics">Vibrio cholerae</content>.</item>
                           <item>Campylobacter fetus infections caused by <content styleCode="italics">Campylobacter fetus</content>.</item>
                           <item>Brucellosis due to <content styleCode="italics">Brucella</content> species (in conjunction with streptomycin).</item>
                           <item>Bartonellosis due to <content styleCode="italics">Bartonella bacilliformis</content>.</item>
                        </list>
                        <paragraph>Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of infections caused by the following gram- negative microorganisms, when bacteriological testing indicates appropriate susceptibility to the drug:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="italics">Escherichia coli</content>
                           </item>
                           <item>
                              <content styleCode="italics">Enterobacter aerogenes</content>
                           </item>
                           <item>
                              <content styleCode="italics">Shigella</content> species</item>
                           <item>
                              <content styleCode="italics">Acinetobacter</content> species</item>
                           <item>Urinary tract infections caused by <content styleCode="italics">Klebsiella</content> species.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.5">
                     <id root="8271c619-37ff-43ba-b3fc-22f7ad1e4cf1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5	Ophthalmic Infections</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for treatment of the following ophthalmic infections:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Trachoma caused by <content styleCode="italics">Chlamydia trachomatis</content>, although the infectious agent is not always eliminated as judged by immunofluorescence.</item>
                           <item>Inclusion conjunctivitis caused by <content styleCode="italics">Chlamydia trachomatis</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.6">
                     <id root="632220b0-dcab-442c-8ee0-a44ccb59ecf7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6	Anthrax Including Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for the treatment of anthrax due to <content styleCode="italics">Bacillus anthracis</content>, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized <content styleCode="italics">Bacillus anthracis</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.7">
                     <id root="30c3f7ac-df47-4292-b4cd-b6e587580e34"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.7	Alternative Treatment for Selected Infections When Penicillin is Contraindicated</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated as an alternative treatment for the following selected infections when penicillin is contraindicated:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Syphilis caused by <content styleCode="italics">Treponema pallidum</content>.</item>
                           <item>Yaws caused by <content styleCode="italics">Treponema pallidum</content> subspecies <content styleCode="italics">pertenue</content>.</item>
                           <item>Vincent's infection caused by <content styleCode="italics">Fusobacterium fusiforme.</content>
                           </item>
                           <item>Actinomycosis caused by <content styleCode="italics">Actinomyces israelii</content>.</item>
                           <item>Infections caused by <content styleCode="italics">Clostridium</content> species.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.8">
                     <id root="c6f59d4f-3267-4a8d-8468-ec30bd4466e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.8	Adjunctive Therapy for Acute Intestinal Amebiasis and Severe Acne</title>
                     <text>
                        <paragraph>In acute intestinal amebiasis, doxycycline hyclate delayed-release tablets may be a useful adjunct to amebicides.</paragraph>
                        <paragraph>In severe acne, doxycycline may be useful adjunctive therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.9">
                     <id root="9fb688e3-7cb3-497f-b8aa-094609502649"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.9	Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are indicated for the prophylaxis of malaria due to <content styleCode="italics">Plasmodium falciparum</content> in short-term travelers (less than 4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains [<content styleCode="italics">see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml> and <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.10">
                     <id root="04279fed-5e66-4329-87d3-adb3a290fe8a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.10	Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate delayed-release tablets and other antibacterial drugs, doxycycline hyclate delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="32fae46d-ee2b-4e1d-a313-8ab497ed6dff"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Dosage in Adult Patients:</content>
                              <list listType="unordered" styleCode="circle">
                                 <item>The usual dosage is 200 mg on the first day of treatment (administered 100 mg every 12 hours) followed by a maintenance dose of 100 mg daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                                 <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Dosage in Pediatric Patients:</content>
                              <list listType="unordered" styleCode="circle">
                                 <item>For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dose is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                                 <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dose is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into two doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="8832b24c-8344-47c2-8cde-4754045333d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Important Dosage and Administration Instructions</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Doxycycline hyclate delayed-release tablets are not substitutable on a mg per mg basis with other oral doxycyclines. To avoid prescribing errors, do not substitute doxycycline hyclate delayed-release tablets for other oral doxycyclines on a mg per mg basis because of differing bioavailability.</item>
                           <item>Do not chew or crush tablets <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>.</item>
                           <item>The recommended dosage, frequency of administration and weight-based dosage recommendations of doxycycline hyclate delayed-release tablets differ from that of the other tetracyclines <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2</linkHtml>, <linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>]</content>. Exceeding the recommended dosage may result in an increased incidence of adverse reactions.</item>
                           <item>Administer doxycycline hyclate delayed-release tablets with an adequate amount of fluid to wash down the drug and reduce the risk of esophageal irritation and ulceration <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>.</item>
                           <item>If gastric irritation occurs, doxycycline hyclate delayed-release tablets may be given with food or milk <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="0c445b28-2a48-41ef-8144-89ef5e15b56e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Switching from Doxycycline Hyclate Delayed-Release Tablets to Doxycycline Hyclate Delayed-Release Tablets (MPC)</title>
                     <text>
                        <paragraph>When switching from doxycycline hyclate delayed-release tablets to doxycycline hyclate delayed-release tablets (MPC):</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>A 60 mg dose of doxycycline hyclate delayed-release tablets (MPC) will replace a 50 mg dose of doxycycline hyclate delayed-release tablets</item>
                           <item>A 120 mg dose of doxycycline hyclate delayed-release tablets (MPC) will replace a 100 mg dose of doxycycline hyclate delayed-release tablets</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="d5a9f61c-b37f-41a7-b295-ce9a844433f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage in Adult Patients</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The usual dosage of doxycycline hyclate delayed-release tablets is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.</item>
                           <item>The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. </item>
                           <item>In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.</item>
                           <item>For certain selected specific indications, the recommended duration or dosage and duration of doxycycline hyclate delayed-release tablets (MPC) in adult patients are as follows:<list listType="ordered">
                                 <item>Streptococcal infections, therapy should be continued for 10 days.</item>
                                 <item>Uncomplicated urethral, endocervical, or rectal infection caused by <content styleCode="italics">C. trachomatis</content>: 100 mg, by mouth, twice-a-day for 7 days.</item>
                                 <item>Uncomplicated gonococcal infections in adults (except anorectal infections in men): 100 mg, by mouth, twice-a-day for 7 days. As an alternate single visit dose, administer 300 mg followed in one hour by a second 300 mg dose.</item>
                                 <item>Nongonococcal urethritis (NGU) caused by <content styleCode="italics">U. urealyticum</content>: 100 mg, by mouth, twice-a-day for 7 days.</item>
                                 <item>Syphilis – early: Patients who are allergic to penicillin should be treated with doxycycline 120 mg, by mouth, twice-a-day for 2 weeks.</item>
                                 <item>Syphilis of more than one year's duration: Patients who are allergic to penicillin should be treated with doxycycline 100 mg, by mouth, twice-a-day for 4 weeks.</item>
                                 <item>Acute epididymo-orchitis caused by <content styleCode="italics">N. gonorrhoeae</content>: 100 mg, by mouth, twice-a-day for at least 10 days.</item>
                                 <item>Acute epididymo-orchitis caused by <content styleCode="italics">C. trachomatis</content>: 100 mg, by mouth, twice-a-day for at least 10 days</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="7507da2e-52f3-4064-a661-98814bec664c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Dosage in Pediatric Patients</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>For all pediatric patients weighing less than 45 kg with severe or life threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage of doxycycline is 2.2 mg per kg of body weight administered every 12 hours. Pediatric patients weighing 45 kg or more should receive the adult dose <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</item>
                           <item>For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule of doxycycline is 4.4 mg per kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used.</item>
                        </list>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="c56495c2-7579-46d2-889d-da18ba8ff49d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5	Dosage for Prophylaxis of Malaria</title>
                     <text>
                        <paragraph>For adults, the recommended dose of doxycycline hyclate delayed-release tablets is 100 mg daily. For pediatric patients 8 years of age and older, the recommended dose is 2 mg/kg administered once daily up to the adult dose. Pediatric patients weighing 45 kg or more should receive the adult dose.</paragraph>
                        <paragraph>Prophylaxis should begin 1 or 2 days before travel to the malarious area. Prophylaxis should be continued daily during travel in the malarious area and for 4 weeks after the traveler leaves the malarious area.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="482417dd-5bbd-4cac-bb58-62f11f875a3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6	Dosage for Inhalational Anthrax (Post-Exposure)</title>
                     <text>
                        <paragraph>For adults the recommended dosage is 100 mg of doxycycline hyclate delayed-release tablets, by mouth, twice-a-day for 60 days.</paragraph>
                        <paragraph>For pediatric patients weighing less than 45 kg, the recommended dosage of doxycycline hyclate delayed-release tablets is 2.2 mg/kg of body weight, by mouth, twice-a-day for 60 days. Pediatric patients weighing 45 kg or more should receive the adult dose.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.7">
                     <id root="9cdf0873-69a1-4f6b-9e58-e4afa360c09c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7	Sprinkling the Tablet Over Applesauce</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets may also be administered by carefully breaking up the tablet and sprinkling the tablet contents (delayed-release pellets) on a spoonful of applesauce. The delayed-release pellets must not be crushed or damaged when breaking up the tablet. Any loss of pellets in the transfer would prevent using the dose. The applesauce/doxycycline hyclate delayed-release tablets mixture should be swallowed immediately without chewing and may be followed by a glass of water if desired. The applesauce should not be hot, and it should be soft enough to be swallowed without chewing. In the event that a prepared dose of applesauce/doxycycline hyclate delayed-release tablets mixture cannot be taken immediately, the mixture should be discarded and not stored for later use.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="c533ff88-4c1c-4877-ba98-c6f98f2db451"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Doxycycline hyclate delayed-release tablets, USP 80 mg are white, oval scored tablets containing yellow pellets and debossed with "D|8" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 80 mg of doxycycline.</paragraph>
                  <paragraph>Doxycycline hyclate delayed-release tablets, 200 mg are white, oval scored tablets containing yellow pellets and debossed with "D|D" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 200 mg of doxycycline.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline Hyclate Delayed-Release Tablets: 80 mg, and 200 mg (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="265a2a0a-f247-4557-9f9a-a5250e64b780"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Doxycycline hyclate delayed-release tablets are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. </paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets are contraindicated in persons who have shown hypersensitivity to any of the tetracyclines. (<linkHtml href="#S4">4</linkHtml> )</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="cd137fe3-013c-4cfa-badf-ce7b09480344"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Clostridioides difficile</content>-associated diarrhea (CDAD) has been reported: Evaluate patients if diarrhea occurs. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Limit sun exposure. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Overgrowth of non-susceptible organisms, including fungi, may occur. If such infections occur, discontinue use and institute appropriate therapy. (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="d407d05c-d376-4a56-9ff2-17d330fec0b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Tooth Development</title>
                     <text>
                        <paragraph>The use of drugs of the tetracycline-class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Use doxycycline hyclate delayed-release tablets in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="918a2c89-a7a2-49ba-88b2-3b2b29ce1c2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	<content styleCode="italics">Clostridioides difficile-</content>Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline hyclate delayed-release tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C<content styleCode="bold">.</content> difficile</content>, and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="f90132f2-6a92-4ac9-ae12-193b7c552453"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Photosensitivity</title>
                     <text>
                        <paragraph>Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="f5af08f4-318b-4dec-b0aa-f167904f6d49"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Potential for Microbial Overgrowth</title>
                     <text>
                        <paragraph>Doxycycline hyclate delayed-release tablets may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibacterial should be discontinued and appropriate therapy instituted.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="df4635ab-c168-4cb4-bf84-4339fab0582c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Severe Skin Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. Fixed drug eruptions have occurred with doxycycline and have been associated with worsening severity upon subsequent administrations, including generalized bullous fixed drug eruption <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]</content>. If severe skin reactions occur, discontinue  doxycycline hyclate delayed-release tablets immediately and institute appropriate therapy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="fdb52f98-ca20-4259-b775-45409d37621c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6	Intracranial Hypertension</title>
                     <text>
                        <paragraph>Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline including doxycycline hyclate delayed-release tablets. Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Avoid concomitant use of isotretinoin and doxycycline hyclate delayed-release tablets because isotretinoin is also known to cause pseudotumor cerebri. </paragraph>
                        <paragraph>Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="21e28e99-451c-47b8-9394-2dc804fa20f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7	Skeletal Development</title>
                     <text>
                        <paragraph>All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued.</paragraph>
                        <paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="bf586f51-9286-485f-9904-d74248713332"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8	Antianabolic Action</title>
                     <text>
                        <paragraph>The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients with impaired renal function.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="1587cd62-b9da-475b-bd64-9fc4ecbf248c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9	Malaria</title>
                     <text>
                        <paragraph>Doxycycline offers substantial but not complete suppression of the asexual blood stages of <content styleCode="italics">Plasmodium</content> strains.</paragraph>
                        <paragraph>Doxycycline does not suppress <content styleCode="italics">P. falciparum's</content> sexual blood stage gametocytes. Subjects completing this prophylactic regimen may still transmit the infection to mosquitoes outside endemic areas.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="bf8d0d3c-5559-4521-9b23-0083091911f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10	Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing doxycycline hyclate delayed-release tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="915e287a-f175-40a8-982b-32a7a43b8262"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11	Laboratory Monitoring for Long-Term Therapy</title>
                     <text>
                        <paragraph>In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic studies should be performed.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="4332958c-c63c-42cb-975d-b13608d89a6c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia. (<linkHtml href="#S6">6</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or <content styleCode="underline">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="d1a9fd86-8bd1-4d7b-aaee-924c7fcd449d"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trial Experience</title>
                     <text>
                        <paragraph>The safety and efficacy of doxycycline hyclate delayed-release tablets, 200 mg as a single daily dose was evaluated in a multicenter, randomized, double-blind, active-controlled study. Doxycycline hyclate delayed-release tablets, 200 mg was given orally once-a-day for 7 days and compared to doxycycline hyclate capsules 100 mg given orally twice daily for 7 days for the treatment of men and women with uncomplicated urogenital <content styleCode="italics">C. trachomatis</content> infection. </paragraph>
                        <paragraph>Adverse reactions in the Safety Population were reported by 99 (40.2%) subjects in the doxycycline hyclate delayed-release tablets, 200 mg treatment group and 132 (53.2%) subjects in the doxycycline hyclate capsules reference treatment group. Most adverse reactions were mild in intensity. The most commonly reported adverse reactions in both treatment groups were nausea, vomiting, diarrhea, and bacterial vaginitis, Table 1.</paragraph>
                        <table width="75%">
                           <caption>Table 1: Adverse Reactions Reported in Greater than or Equal to 2% of Subjects</caption>
                           <col width="50%" align="left" valign="top"/>
                           <col width="50%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reactions</th>
                                 <th styleCode="Rrule">Doxycycline hyclate delayed-release tablets Tablets, 200 mg <br/>N = 246</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule"/>
                                 <td styleCode="Rrule">n (%)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Subjects with any AE</td>
                                 <td styleCode="Rrule">99 (40.2)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Nausea</td>
                                 <td styleCode="Rrule">33 (13.4)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Vomiting</td>
                                 <td styleCode="Rrule">20 (8.1)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Headache</td>
                                 <td styleCode="Rrule">5 (2.0)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Diarrhea</td>
                                 <td styleCode="Rrule">8 (3.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Abdominal Pain Upper</td>
                                 <td styleCode="Rrule">5 (2.0)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">  Vaginitis Bacterial</td>
                                 <td styleCode="Rrule">8 (3.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">  Vulvovaginal Mycotic Infection</td>
                                 <td styleCode="Rrule">5 (2.0)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Because clinical trials are conducted under prescribed conditions, adverse reaction rates observed in the clinical trial may not always reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="8217390d-f124-41b7-b93e-6266b2840a8a"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of doxycycline. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate a causal relationship to drug exposure.</paragraph>
                        <paragraph>Due to oral doxycycline's virtually complete absorption, side effects to the lower bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal</content>: Anorexia, nausea, vomiting, diarrhea, glossitis, dysphagia, enterocolitis, inflammatory lesions (with monilial overgrowth) in the anogenital region and pancreatitis. Hepatotoxicity has been reported. These reactions have been caused by both the oral and parenteral administration of tetracyclines. Superficial discoloration of the adult permanent dentition, reversible upon drug discontinuation and professional dental cleaning has been reported. Permanent tooth discoloration and enamel hypoplasia may occur with drugs of the tetracycline class when used during tooth development <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. Esophagitis and esophageal ulcerations have been reported in patients receiving capsule and tablet forms of drugs in the tetracycline- class. Most of these patients took medications immediately before going to bed [<content styleCode="italics">see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin</content>: Maculopapular and erythematous rashes, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, and fixed drug eruption have been reported. Photosensitivity is discussed above [<content styleCode="italics">see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal</content>: Rise in BUN has been reported and is apparently dose-related [<content styleCode="italics">see <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity reactions</content>: Urticaria, angioneurotic edema, anaphylaxis, anaphylactoid purpura, serum sickness, pericarditis, and exacerbation of systemic lupus erythematosus, and drug reaction with eosinophilia and systemic symptoms (DRESS).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood</content>: Hemolytic anemia, thrombocytopenia, neutropenia, and eosinophilia have been reported.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Intracranial Hypertension</content>: Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracycline [<content styleCode="italics">see <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>
                           </content>]</paragraph>
                        <paragraph>
                           <content styleCode="italics">Thyroid Gland Changes</content>: When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of thyroid glands. No abnormalities of thyroid function are known to occur.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content> Depression, anxiety, suicidal ideation, insomnia, abnormal dreams, hallucination</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="4a8565c5-84c0-4cc9-9e6c-7e92c1238b40"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>Avoid co-administration of tetracyclines with penicillin (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                           <item>Absorption of tetracyclines, including Doxycycline hyclate delayed-release tablets, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations (<linkHtml href="#S7.3">7.3</linkHtml>)</item>
                           <item>Concurrent use of tetracyclines, including Doxycycline hyclate delayed-release tablets, may render oral contraceptives less effective (<linkHtml href="#S7.4">7.4</linkHtml>)</item>
                           <item>Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline (<linkHtml href="#S7.5">7.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="cea355e9-c3a5-4b03-a00d-16d87ae9e0d2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Anticoagulant Drugs</title>
                     <text>
                        <paragraph>Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="0b10e6d2-815b-4c65-b7c1-cb42d210a682"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Penicillin</title>
                     <text>
                        <paragraph>Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="ed879fcf-4303-4b73-822d-435126be15be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3	Antacids and Iron Preparations</title>
                     <text>
                        <paragraph>Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron-containing preparations.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="7dff1518-5b8e-49ce-8a0a-bab71aa33dff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4	Oral Contraceptives</title>
                     <text>
                        <paragraph>Concurrent use of tetracycline may render oral contraceptives less effective.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="ed845a99-a22c-4dba-8659-7a38e750d655"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5	Barbiturates and Anti-Epileptics</title>
                     <text>
                        <paragraph>Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="2cf75b32-f892-4c8f-a556-a56aaa60838c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6	Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>False elevations of urinary catecholamines may occur due to interference with the fluorescence test.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="aa2337ba-eaf7-4f12-943f-50e4a9420a02"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250331"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Tetracycline-class drugs can cause fetal harm when administered to a pregnant woman, but data for doxycycline are limited. (<linkHtml href="#S5.6">5.6</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>)</item>
                           <item>Tetracyclines are excreted in human milk; however, the extent of absorption of doxycycline in the breastfed infant is not known. Doxycycline hyclate delayed-release tablets use during nursing should be avoided if possible. (<linkHtml href="#S8.2">8.2</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="cf83b394-8f2c-4e26-997c-cbddcb1edb8b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="ce38293d-bbd8-4630-9841-43851ac43473"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate and well-controlled studies on the use of doxycycline in pregnant women. The vast majority of reported experience with doxycycline during human pregnancy is short-term, first trimester exposure. There are no human data available to assess the effects of long-term therapy of doxycycline in pregnant women such as that proposed for the treatment of anthrax exposure. An expert review of published data on experiences with doxycycline use during pregnancy by TERIS - the Teratogen Information System - concluded that therapeutic doses during pregnancy are unlikely to pose a substantial teratogenic risk (the quantity and quality of data were assessed as limited to fair), but the data are insufficient to state that there is no risk <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.<sup>1</sup>
                              </paragraph>
                              <paragraph>In the US general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="038448b0-6715-4086-bdef-0e8db41b89a6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="1ff9dab9-37bd-4cca-bb02-4e29cab2356d"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity also has been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking these drugs, the patient should be apprised of the potential hazard to the fetus <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="d555393c-e001-4971-80e1-9ba73ef9ae16"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="ed8054ad-b2b1-48b1-8476-873a6faecbc4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>A case-control study (18,515 mothers of infants with congenital anomalies and 32,804 mothers of infants with no congenital anomalies) shows a weak but marginally statistically significant association with total malformations and use of doxycycline anytime during pregnancy. Sixty-three (0.19%) of the controls and 56 (0.30%) of the cases were treated with doxycycline. This association was not seen when the analysis was confined to maternal treatment during the period of organogenesis (that is, in the second and third months of gestation), with the exception of a marginal relationship with neural tube defect based on only two-exposed cases.<sup>2</sup>
                                    </paragraph>
                                    <paragraph>A small prospective study of 81 pregnancies describes 43 pregnant women treated for 10 days with doxycycline during early first trimester. All mothers reported their exposed infants were normal at 1 year of age.<sup>3</sup>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="216ed717-f786-4a19-a78e-4111cfa0bfc8"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	 Lactation </title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="23c4595d-31cc-4fd3-abd5-b326b156b330"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Tetracyclines are excreted in human milk, however, the extent of absorption of tetracyclines including doxycycline, by the breastfed infant is not known. Short-term use by lactating women is not necessarily contraindicated. The effects of prolonged exposure to doxycycline in breast milk production and breast fed neonates, infants and children are unknown<sup>4</sup>. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for doxycycline hyclate delayed-release tablets and any potential adverse effects on the breast fed child from doxycycline hyclate delayed-release tablets or from the underlying maternal condition [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>
                                 </content>].</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="303cbd03-1872-497a-8d07-7275f26bbe5c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric use</title>
                     <text>
                        <paragraph>Because of the effects of drugs of the tetracycline-class on tooth development and growth, use doxycycline hyclate delayed-release tablets in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly, when there are no alternative therapies [<content styleCode="italics">see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.3">2.3)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.6">5.6)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="b4919511-fe1b-42a5-8caf-aabc5f75151c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric use</title>
                     <text>
                        <paragraph>Clinical studies of doxycycline hyclate delayed-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 50 mg contain 3 mg (0.131 mEq) of sodium.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 75 mg contain 4.5 mg (0.196 mEq) of sodium.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 80 mg contain 4.8 mg (0.209 mEq) of sodium.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 100 mg contain 6 mg (0.261 mEq) of sodium.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 150 mg contain 9 mg (0.392 mEq) of sodium.</paragraph>
                        <paragraph>Doxycycline hyclate delayed-release tablets, USP, 200 mg contain 12 mg (0.522 mEq) of sodium.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="cdcd5f43-81da-41ea-ae93-0e785a214120"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="92e149c7-4ac7-41b4-bd07-071dc1ea452b"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Doxycycline hyclate delayed-release tablets, contain specially coated pellets of doxycycline hyclate, a tetracycline class drug synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration.</paragraph>
                  <paragraph>The structural formula for doxycycline hyclate is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>with a molecular formula of C<sub>22</sub>H<sub>24</sub>N<sub>2</sub>O<sub>8</sub>, HCl, ½ C<sub>2</sub>H<sub>6</sub>O, ½ H<sub>2</sub>O and a molecular weight of 512.9. The chemical name for doxycycline hyclate is [4S(4aR,5S,5aR,6R,12aS)]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6- methyl-1,11-deoxonaphthacene-2-carboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.</paragraph>
                  <paragraph>Each tablet contains doxycycline 50 mg, 75 mg, 80 mg, 100 mg, 150 mg or 200 mg (equivalent to doxycycline hyclate 57.7 mg, 86.6 mg, 92.3 mg, 115.4 mg, 173.1 mg or 230.8 mg). Inactive ingredients in the tablet formulation are: lactose monohydrate; microcrystalline cellulose; sodium lauryl sulfate; sodium chloride; talc; anhydrous lactose; corn starch; crospovidone; magnesium stearate; cellulosic polymer coating.</paragraph>
                  <paragraph>Each doxycycline hyclate delayed-release tablets 50 mg tablet contains 3 mg (0.131 mEq) of sodium, each doxycycline hyclate delayed-release tablets 75 mg tablet contains 4.5 mg (0.196 mEq) of sodium, each doxycycline hyclate delayed-release tablets 80 mg tablet contains 4.8 mg (0.209 mEq) of sodium, each doxycycline hyclate delayed-release tablets 100 mg tablet contains 6 mg (0.261 mEq) of sodium, each doxycycline hyclate delayed-release tablets 150 mg tablet contains 9 mg (0.392 mEq) of sodium, and each doxycycline hyclate delayed-release tablets 200 mg tablet contains 12 mg (0.522 mEq) of sodium.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="5fec519c-d497-47c7-a843-300ccf5a4a1b"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S12.1">
                     <id root="746f6f88-559b-4f1a-ae43-2964f83ca6c4"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Doxycycline is a tetracycline-class antimicrobial drug [<content styleCode="italics">see <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="c1c5619d-8fe1-4956-a143-9c7bcc020a3f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following single and multiple-dose administration of doxycycline hyclate delayed-release tablets, 200 mg to adult volunteers, average peak plasma doxycycline concentration (C<sub>max</sub>) was 4.6 mcg/mL and 6.3 mcg/mL, respectively with median t<sub>max</sub> of 3 hours; the corresponding mean plasma concentration values 24 hours after single and multiple doses were 1.5 mcg/mL and 2.3 mcg/mL, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="c7718235-85dd-408e-9336-ea09b9b77e86"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Doxycycline is virtually completely absorbed after oral administration.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="721df149-f14b-4f93-a6d5-b63e6a950d61"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>The mean C<sub>max</sub> and AUC <sub>0-∞</sub> of doxycycline are 24% and 13% lower, respectively, following single dose administration of doxycycline hyclate delayed-release tablets, 100 mg with a high fat meal (including milk) compared to fasted conditions. The mean C<sub>max</sub> of doxycycline is 19% lower and the AUC <sub>0-∞</sub> is unchanged following single dose administration of doxycycline hyclate delayed-release tablets, 150 mg with a high fat meal (including milk) compared to fasted conditions. The clinical significance of these decreases is unknown. Doxycycline bioavailability from doxycycline hyclate delayed-release tablets, 200 mg was not affected by food, but the incidence of nausea was higher in fasted subjects. The 200 mg tablets may be administered without regard to meals.</paragraph>
                                    <paragraph>When doxycycline hyclate delayed-release tablets are sprinkled over applesauce and taken with or without water, the extent of doxycycline absorption is unchanged, but the rate of absorption is increased slightly.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="346db10c-afdf-4274-b95e-72853d8c61f4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Tetracyclines are concentrated in bile by the liver and excreted in the urine and feces at high concentrations and in a biologically active form. Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with a creatinine clearance of about 75 mL/min. This percentage may fall as low as 1-5%/72 hours in individuals with a creatinine clearance below 10 mL/min.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e47b89bf-e915-4973-832f-bd32f8323a4a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                           <component>
                              <section>
                                 <id root="8fbbf650-f00d-456b-badc-4c30c72a3d78"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Studies have shown no significant difference in the serum half-life of doxycycline (range 18 to 22 hours) in individuals with normal and severely impaired renal function. Hemodialysis does not alter the serum half-life.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="d1b252da-a473-4cc9-91bd-15c99c43afad"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>Population pharmacokinetic analysis of sparse concentration-time data of doxycycline. Following standard of care intravenous and oral dosing in 44 children (2-18 years of age) showed that allometrically-scaled clearance of doxycycline in children ≥2 to ≤8 years of age (median [range] 3.58 [2.27-10.82] L/h/70 kg, N=11) did not differ significantly from children &gt;8 to 18 years of age (3.27 [1.11-8.12] L/h/70 kg, N=33). For pediatric patients weighing ≤45 kg, body weight normalized doxycycline CL in those ≥2 to ≤8 years of age (median [range] 0.071 [0.041-0.202] L/kg/h, N=l0) did not differ significantly from those &gt;8 to 18 years of age (0.081 [0.035-0.126] L/kg/h, N=8). In pediatric patients weighing &gt;45 kg no clinically significant differences in body weight normalized doxycycline CL were observed between those ≥2 to ≤8 years (0.050 L/kg/h, N=l) and those &gt;8 years of age (0.044 [0.014-0.121] L/kg/h, N=25). No clinically significant difference in CL differences between oral and IV were observed in the small cohort of pediatric patients who received the oral (N=l9) or IV (N=21) formulation alone.</paragraph>
                                 </text>
                                 <effectiveTime value="20250331"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="a124e9b4-f034-433a-a157-c0edf109c3de"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4	Microbiology</title>
                     <effectiveTime value="20250331"/>
                     <component>
                        <section>
                           <id root="3333e3d6-47df-48f7-9334-08a6c003cac3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6dbfe24b-c956-40dd-9267-e137420450a7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                              <paragraph>Cross-resistance between tetracyclines is common.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="be1bc708-3400-48bc-9135-9bc6f73617fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antimicrobial Activity</content>
                              </paragraph>
                              <paragraph>Doxycycline has been shown to be active against most isolates of the following microorganisms, both <content styleCode="italics">in vitro</content> and in clinical infections. [<content styleCode="italics">see <linkHtml href="#S1">Indications and Usage (1)</linkHtml>
                                 </content>].</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Gram-Negative Bacteria </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Acinetobacter</content> species<br/>
                                 <content styleCode="italics">Bartonella bacilliformis<br/>Brucella</content> species<br/>
                                 <content styleCode="italics">Campylobacter fetus<br/> Enterobacter aerogenes <br/>Escherichia coli<br/>Francisella tularensis<br/> Haemophilus ducreyi<br/> Haemophilus influenzae<br/>Klebsiella granulomatis <br/>Klebsiella</content> species<br/>
                                 <content styleCode="italics">Neisseria gonorrhoeae<br/>Shigella</content> species<br/>
                                 <content styleCode="italics">Vibrio cholerae<br/>Yersinia pestis</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Gram-Positive Bacteria </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Bacillus anthracis <br/>Listeria monocytogenes<br/>Streptococcus pneumoniae</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Anaerobic Bacteria </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Clostridium</content> species <br/>
                                 <content styleCode="italics">Fusobacterium fusiforme<br/> Propionibacterium acnes</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Other Bacteria </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Norcardiae</content> and other aerobic <content styleCode="italics">Actinomyces</content> species<br/>
                                 <content styleCode="italics">Borrelia recurrentis<br/>Chlamydophila psittaci <br/>Chlamydia trachomatis<br/>Mycoplasma pneumoniae</content>
                                 <br/>Rickettsiae<br/>
                                 <content styleCode="italics">Treponema pallidum <br/>Treponema pallidum</content> subspecies <content styleCode="italics">pertenue</content>
                                 <br/>
                                 <content styleCode="italics">Ureaplasma urealyticum</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Parasites</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Balantidium coli<br/>Entamoeba</content> species<br/>
                                 <content styleCode="italics">Plasmodium falciparum</content>
                                 <footnote>Doxycycline has been found to be active against the asexual erythrocytic forms of <content styleCode="italics">Plasmodium falciparum</content> but not against the gametocytes of <content styleCode="italics">P. falciparum.</content> The precise mechanism of action of the drug is not known.</footnote>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="0fb97b00-8c56-4088-a792-f39620f2b4e6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Susceptibility Testing</content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.</paragraph>
                           </text>
                           <effectiveTime value="20250331"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="0e67c05e-443d-439c-8149-c19ae13db4ef"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S13.1">
                     <id root="a7a823b2-6b69-4c7c-a8aa-fe444dd0339d"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals to evaluate carcinogenic potential of doxycycline have not been conducted. However, there has been evidence of oncogenic activity in rats in studies with the related antibacterials, oxytetracycline (adrenal and pituitary tumors) and minocycline (thyroid tumors). Likewise, although mutagenicity studies of doxycycline have not been conducted, positive results in <content styleCode="italics">in vitro</content> mammalian cell assays have been reported for related antibacterials (tetracycline, oxytetracycline).</paragraph>
                        <paragraph>Doxycycline administered orally at dosage levels as high as 250 mg/kg/day had no apparent effect on the fertility of female rats. Effect on male fertility has not been studied.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="aad33400-585d-42ba-a109-02e86dec13a6"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Hyperpigmentation of the thyroid has been produced by members of the tetracycline- class in the following species: in rats by oxytetracycline, doxycycline, tetracycline PO<sub>4</sub>, and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO<sub>4</sub>, and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.</paragraph>
                        <paragraph>Minocycline, tetracycline PO<sub>4</sub>, methacycline, doxycycline, tetracycline base, oxytetracycline HCl, and tetracycline HCl, were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accompanied by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.</paragraph>
                        <paragraph>Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline); in chickens (chlortetracycline); and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.</paragraph>
                        <paragraph>Results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues.</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="672af220-9503-4d31-945d-57ad0fd93f7b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>This was a randomized, double-blind, active-controlled, multicenter trial which enrolled 495 subjects, between 19 to 45 years of age with a confirmed diagnosis of urogenital <content styleCode="italics">C. trachomatis</content> infection less than 14 days prior to enrollment, or partner(s) of a subject with a known positive test for urogenital <content styleCode="italics">C. trachomatis</content> infection.</paragraph>
                  <paragraph>The primary purpose of this study was to evaluate the efficacy and safety of doxycycline hyclate delayed-release tablets Tablets, 200 mg once daily versus doxycycline hyclate capsules, 100 mg twice daily for seven days for the treatment of uncomplicated urogenital <content styleCode="italics">C. trachomatis</content> infection. The primary efficacy objective was to demonstrate non-inferiority of the doxycycline hyclate delayed-release tablets, 200 mg once daily treatment regimen versus the doxycycline 100 mg twice daily treatment regimen for the indication using a negative nucleic acid amplification test (NAAT) at the test of cure visit (day 28) in the mITT population (subjects who were positive at baseline and took at least one day of study drug).</paragraph>
                  <table width="90%" ID="table2">
                     <caption>Table 2: Primary Efficacy Outcome – Microbiological Cure of C. trachomatis at Day 28</caption>
                     <col width="5%" align="left" valign="top"/>
                     <col width="35%" align="left" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <col width="20%" align="center" valign="top"/>
                     <thead>
                        <tr styleCode="Botrule">
                           <th align="center" styleCode="Lrule Rrule" colspan="2">mITT Population</th>
                           <th styleCode="Rrule">Doxycycline hyclate delayed-release tablets, 200 mg once daily<br/>Cure Rate (%)</th>
                           <th styleCode="Rrule">Doxycycline hyclate capsules, 100 mg twice daily<br/>Cure Rate (%)</th>
                           <th styleCode="Rrule">Difference<br/>(%)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">N</td>
                           <td styleCode="Rrule">188</td>
                           <td styleCode="Rrule">190</td>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">Microbiological Cure, n (%)</td>
                           <td styleCode="Rrule">163 (86.7)</td>
                           <td styleCode="Rrule">171 (90.0)</td>
                           <td styleCode="Rrule">-3.3%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule"/>
                           <td styleCode="Rrule">95% Confidence Interval for Cure Rate</td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule">-10.3, 3.7</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="S15">
               <id root="301b21db-0a6e-4400-81b7-d0dab13d288a"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>1. Friedman JM, Polifka JE. <content styleCode="italics">Teratogenic Effects of Drug</content>s. <content styleCode="italics">A Resource for Clinicians</content> (TERIS). Baltimore, MD: The Johns Hopkins University Press: 2000: 149-195.</paragraph>
                  <paragraph>2. Cziezel AE and Rockenbauer M. Teratogenic study of doxycycline. <content styleCode="italics">Obstet Gynecol</content> 1997; 89: 524-528.</paragraph>
                  <paragraph>3. Horne HW Jr. and Kundsin RB. The role of mycoplasma among 81 consecutive pregnancies: a prospective study. <content styleCode="italics">Int J Fertil</content> 1980; 25: 315-317.</paragraph>
                  <paragraph>4. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); [Last Revision Date 2015 March 10; cited 2016 Jan]. Doxycycline; LactMed Record Number: 100; [about 3 screens]. Available from: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm .</paragraph>
               </text>
               <effectiveTime value="20250331"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="7678857a-e95b-4ccb-858d-2251b1ad063e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Doxycycline hyclate delayed-release tablets, USP, 80 mg are white, oval scored tablets containing yellow pellets and debossed with "D|8" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 80 mg of doxycycline.</paragraph>
                  <paragraph>Bottles of 30 tablets<br/>
                     <content styleCode="bold">NDC</content> 51862-571-30</paragraph>
                  <paragraph>Doxycycline hyclate delayed-release tablets, 200 mg are white, oval scored tablets containing yellow pellets and debossed with "D|D" on one face and plain on the other. Each tablet contains specially coated pellets of doxycycline hyclate equivalent to 200 mg of doxycycline.</paragraph>
                  <table width="50%" styleCode="Noautorules">
                     <col width="45%" align="left" valign="top"/>
                     <col width="55%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottles of 30 tablets </td>
                           <td>Bottles of 60 tablets</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">NDC</content> 68308-716-30 </td>
                           <td>
                              <content styleCode="bold">NDC</content> 68308-716-60</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <section>
                     <id root="aeeff6eb-3ebb-47a3-bd27-80fa853ae225"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container (USP).</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="2bd29a77-8c7e-4a2e-9e5b-3d34f3f3a512"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients taking doxycycline for malaria prophylaxis:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>that no present-day antimalarial agent, including doxycycline, guarantees protection against malaria.</item>
                     <item>to avoid being bitten by mosquitoes by using personal protective measures that help avoid contact with mosquitoes, especially from dusk to dawn (for example, staying in well-screened areas, using mosquito nets, covering the body with clothing, and using an effective insect repellent).</item>
                     <item>that doxycycline prophylaxis: 							<list listType="unordered" styleCode="disc">
                           <item>should begin 1 to 2 days before travel to the malarious area,</item>
                           <item>should be continued daily while in the malarious area and after leaving the malarious area,</item>
                           <item>should be continued for 4 further weeks to avoid development of malaria after returning from an endemic area,</item>
                           <item>should not exceed 4 months.</item>
                        </list>
                     </item>
                  </list>
                  <paragraph>Advise all patients taking doxycycline:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>to avoid excessive sunlight or artificial ultraviolet light while receiving doxycycline and to discontinue therapy if phototoxicity (for example, skin eruptions, etc.) occurs. Sunscreen or sunblock should be considered [<content styleCode="italics">see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                        </content>].</item>
                     <item>to drink fluids liberally along with doxycycline to reduce the risk of esophageal irritation and ulceration [<content styleCode="italics">see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>
                        </content>].</item>
                     <item>that the absorption of tetracyclines is reduced when taken with foods, especially those that contain calcium. However, the absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk [<content styleCode="italics">see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                        </content>].</item>
                     <item>that the absorption of tetracyclines is reduced when taken with antacids containing aluminum, calcium or magnesium, bismuth subsalicylate, and iron-containing preparations [<content styleCode="italics">see <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>
                        </content>].</item>
                     <item>that the use of doxycycline might increase the incidence of vaginal candidiasis.</item>
                  </list>
                  <paragraph>Advise patients that diarrhea is a common problem caused by antibacterials which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of antibacterial. If this occurs, patients should contact their physician as soon as possible.</paragraph>
                  <paragraph>Patients should be counseled that antibacterial drugs including doxycycline hyclate delayed-release tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When doxycycline hyclate delayed-release tablets is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Doxycycline hyclate delayed-release tablets or other antibacterial drugs in the future.</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <section ID="S17.1">
                     <id root="c63b18a8-d37b-434e-8835-2e391c308fe4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Instructions for Breaking the 150 mg Doxycycline Hyclate Delayed-Release Dual-Scored Tablet</title>
                     <text>
                        <paragraph>The tablet is marked with separation lines (score lines) and may be broken at these score lines to provide any of the following doses.</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>150 mg treatment (the entire tablet is taken)<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM2"/>
                              </paragraph>
                           </item>
                           <item>100 mg treatment (two thirds of the tablet or two 50 mg tablet segments are taken)<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM3"/>
                              </paragraph>
                           </item>
                           <item>50 mg treatment (one third of the tablet is taken)<br/>
                              <paragraph>
                                 <renderMultiMedia referencedObject="MM4"/>
                              </paragraph>
                           </item>
                        </list>
                        <paragraph>To break the tablet, the tablet is held between the thumbs and index fingers close to the appropriate score line. Then, with the score line facing the patient, enough pressure is applied to snap the tablet segments apart (segments that do not break along the score line should not be used).</paragraph>
                     </text>
                     <effectiveTime value="20250331"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="doxycycline-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="doxycycline-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Image</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="doxycycline-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="52a32353-488c-4451-88c0-595bd31a3285"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>FDA-Approved Patient Labeling<br/> Doxycycline hyclate delayed-release tablets, 50 mg, 75 mg, 80 mg, 100 mg, 150 mg and 200 mg</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Breaking the 150 mg Doxycycline hyclate delayed-release dual-scored tablet</content>
                  </paragraph>
                  <paragraph>Your doctor may find it necessary to adjust your dosage of doxycycline hyclate delayed-release tablets to obtain the proper treatment response. The tablet is marked with separation lines (score lines) and may be broken at these score lines to provide any of the following doses. If your doctor prescribed:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>150 mg treatment (take the entire tablet)<br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM5"/>
                        </paragraph>
                     </item>
                     <item>100 mg treatment (take two thirds of the tablet or two 50 mg tablet segments)<br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM6"/>
                        </paragraph>
                     </item>
                     <item>50 mg treatment (take one third of the tablet)<br/>
                        <paragraph>
                           <renderMultiMedia referencedObject="MM7"/>
                        </paragraph>
                     </item>
                  </list>
                  <paragraph>To break the tablet, hold the tablet between your thumbs and index fingers close to the appropriate score line. Then, with the score line facing you, apply enough pressure to snap the tablet segments apart (do not use segments that do not break along the score line).</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Mayne Pharma</content>
                     <br/>Raleigh, NC 27609</paragraph>
                  <paragraph>61449</paragraph>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="7b764712-7693-4ce3-bd1d-92e6ee5872d3"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51862-709-12</paragraph>
                  <paragraph>Doxycycline Hyclate<br/> Delayed-Release<br/> Tablets, USP</paragraph>
                  <paragraph>Do not chew or crush tablets.</paragraph>
                  <paragraph>Each tablet contains specially coated pellets<br/> of doxycycline hyclate equivalent to 50 mg of<br/> doxycycline.</paragraph>
                  <paragraph>50 mg</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>120 Tablets</paragraph>
                  <paragraph>mayne pharma</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="9d88ccbd-1531-4fc4-9ec1-f322b1607cc5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 51862-571-30</paragraph>
                  <paragraph>Doxycycline Hyclate<br/> Delayed-Release Tablets, USP</paragraph>
                  <paragraph>Do not chew or crush tablets.<br/> Each tablet contains specially coated pellets of doxycycline<br/> hyclate equivalent to 80 mg of doxycycline.</paragraph>
                  <paragraph>80 mg</paragraph>
                  <paragraph>Rx Only<br/> 30 Tablets</paragraph>
                  <paragraph>mayne pharma</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20250331"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 80 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="doxycycline-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>